These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 7649958)
41. Magic bullet thinking--why do we continue to perpetuate this fallacy? Rucklidge JJ; Johnstone J; Kaplan BJ Br J Psychiatry; 2013 Aug; 203(2):154. PubMed ID: 23908343 [No Abstract] [Full Text] [Related]
42. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Storebø OJ; Storm MRO; Pereira Ribeiro J; Skoog M; Groth C; Callesen HE; Schaug JP; Darling Rasmussen P; Huus CL; Zwi M; Kirubakaran R; Simonsen E; Gluud C Cochrane Database Syst Rev; 2023 Mar; 3(3):CD009885. PubMed ID: 36971690 [TBL] [Abstract][Full Text] [Related]
43. Effects of stimulant medication on divergent and convergent thinking tasks related to creativity in adults with attention-deficit hyperactivity disorder. McBride M; Appling C; Ferguson B; Gonzalez A; Schaeffer A; Zand A; Wang D; Sam A; Hart E; Tosh A; Fontcha I; Parmacek S; Beversdorf D Psychopharmacology (Berl); 2021 Dec; 238(12):3533-3541. PubMed ID: 34477886 [TBL] [Abstract][Full Text] [Related]
44. Creativity in ADHD: Goal-Directed Motivation and Domain Specificity. Boot N; Nevicka B; Baas M J Atten Disord; 2020 Nov; 24(13):1857-1866. PubMed ID: 28845720 [No Abstract] [Full Text] [Related]
45. Comparison of Creativity between Children with and without Attention Deficit Hyperactivity Disorder: A Case-Control Study. Aliabadi B; Davari-Ashtiani R; Khademi M; Arabgol F Iran J Psychiatry; 2016 Apr; 11(2):99-103. PubMed ID: 27437006 [TBL] [Abstract][Full Text] [Related]
46. Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale. Kovshoff H; Banaschewski T; Buitelaar JK; Carucci S; Coghill D; Danckaerts M; Dittmann RW; Falissard B; Grimshaw DG; Hollis C; Inglis S; Konrad K; Liddle E; McCarthy S; Nagy P; Thompson M; Wong IC; Zuddas A; Sonuga-Barke EJ J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):537-47. PubMed ID: 27007169 [TBL] [Abstract][Full Text] [Related]
47. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Storebø OJ; Ramstad E; Krogh HB; Nilausen TD; Skoog M; Holmskov M; Rosendal S; Groth C; Magnusson FL; Moreira-Maia CR; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Forsbøl B; Simonsen E; Gluud C Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD009885. PubMed ID: 26599576 [TBL] [Abstract][Full Text] [Related]
48. Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice. Del'Guidice T; Lemasson M; Etiévant A; Manta S; Magno LA; Escoffier G; Roman FS; Beaulieu JM Psychopharmacology (Berl); 2014 Jan; 231(1):109-22. PubMed ID: 23912772 [TBL] [Abstract][Full Text] [Related]
49. Effects of methylphenidate on attentional set-shifting in a genetic model of attention-deficit/hyperactivity disorder. Cao AH; Yu L; Wang YW; Wang JM; Yang LJ; Lei GF Behav Brain Funct; 2012 Feb; 8(1):10. PubMed ID: 22369105 [TBL] [Abstract][Full Text] [Related]
50. Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress. Swanson J; Baler RD; Volkow ND Neuropsychopharmacology; 2011 Jan; 36(1):207-26. PubMed ID: 20881946 [TBL] [Abstract][Full Text] [Related]
51. Hyperactivity in boys with attention-deficit/hyperactivity disorder (ADHD): a ubiquitous core symptom or manifestation of working memory deficits? Rapport MD; Bolden J; Kofler MJ; Sarver DE; Raiker JS; Alderson RM J Abnorm Child Psychol; 2009 May; 37(4):521-34. PubMed ID: 19083090 [TBL] [Abstract][Full Text] [Related]
52. When we enhance cognition with Adderall, do we sacrifice creativity? A preliminary study. Farah MJ; Haimm C; Sankoorikal G; Smith ME; Chatterjee A Psychopharmacology (Berl); 2009 Jan; 202(1-3):541-7. PubMed ID: 19011838 [TBL] [Abstract][Full Text] [Related]
53. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. Graham J; Coghill D CNS Drugs; 2008; 22(3):213-37. PubMed ID: 18278977 [TBL] [Abstract][Full Text] [Related]
54. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Wilens TE; Decker MW Biochem Pharmacol; 2007 Oct; 74(8):1212-23. PubMed ID: 17689498 [TBL] [Abstract][Full Text] [Related]
55. Dose-response characteristics of methylphenidate on locomotor behavior and on sensory evoked potentials recorded from the VTA, NAc, and PFC in freely behaving rats. Yang PB; Swann AC; Dafny N Behav Brain Funct; 2006 Jan; 2():3. PubMed ID: 16417623 [TBL] [Abstract][Full Text] [Related]
56. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Arnsten AF; Dudley AG Behav Brain Funct; 2005 Apr; 1(1):2. PubMed ID: 15916700 [TBL] [Abstract][Full Text] [Related]
57. Profiles, co-morbidity and their relationship to treatment of 191 children with AD/HD and their families. Thompson MJ; Brooke XM; West CA; Johnson HR; Bumby EJ; Brodrick P; Pepe G; Laver-Bradbury C; Scott N Eur Child Adolesc Psychiatry; 2004 Aug; 13(4):234-42. PubMed ID: 15365894 [TBL] [Abstract][Full Text] [Related]
59. Safety issues in the use of methylphenidate. An American perspective. Rappley MD Drug Saf; 1997 Sep; 17(3):143-8. PubMed ID: 9306050 [TBL] [Abstract][Full Text] [Related]
60. Do high doses of stimulants impair flexible thinking in attention-deficit hyperactivity disorder? Douglas VI; Barr RG; Desilets J; Sherman E J Am Acad Child Adolesc Psychiatry; 1995 Jul; 34(7):877-85. PubMed ID: 7649958 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]